Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E SRC over exp |
| Therapy | Encorafenib |
| Indication/Tumor Type | colorectal cancer |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E SRC over exp | colorectal cancer | resistant | Encorafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Src-overexpressing colorectal cancer cell lines harboring BRAF V600E were resistant to Braftovi (encorafenib) in culture (PMID: 40481178). | 40481178 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40481178) | Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer. | Full reference... |